Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
US10752670B2 · kind B2 · utility
0Cited by
25References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2016 |
| Grant date | Aug 25, 2020 |
| Priority date | — |
| Expiry date | Jan 8, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.